Clinical Trial

A Phase 2 Study of CRD-4730 in CPVT

Study acronym: CPVT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Protocol Amendment History 1 change
notable Trial sites expanded: 9 -> 12 locations 2026-07-10
Trial Details
NCT Number NCT06658899
Lead Sponsor Cardurion Pharmaceuticals, Inc.
Conditions Catecholaminergic Polymorphic Ventricular Tachycardia
Enrollment 12 participants
Start Date 2025-12-01
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-09